MP-02.12 Active Surveillance of Small Renal Tumours: Clinical Outcomes

Urology ◽  
2011 ◽  
Vol 78 (3) ◽  
pp. S39
Author(s):  
M. Elmussareh ◽  
T. Griffiths
2018 ◽  
Vol 74 (2) ◽  
pp. 157-164 ◽  
Author(s):  
Andrew G. McIntosh ◽  
Benjamin T. Ristau ◽  
Karen Ruth ◽  
Rachel Jennings ◽  
Eric Ross ◽  
...  

2020 ◽  
pp. 1-6
Author(s):  
Alexander Gorshtein ◽  
Ilana Slutzky-Shraga ◽  
Eyal Robenshtok ◽  
Carlos Benbassat ◽  
Dania Hirsch

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Ryan Dorin ◽  
Antonio Cusano ◽  
Max Jackson ◽  
Stuart Kesler ◽  
Anoop Meraney ◽  
...  

2017 ◽  
Vol 21 (81) ◽  
pp. 1-68 ◽  
Author(s):  
Naeem Soomro ◽  
Jan Lecouturier ◽  
Deborah D Stocken ◽  
Jing Shen ◽  
Ann Marie Hynes ◽  
...  

Background There is uncertainty around the appropriate management of small renal tumours. Treatments include partial nephrectomy, ablation and active surveillance. Objectives To explore the feasibility of a randomised trial of ablation versus active surveillance. Design Two-stage feasibility study: stage 1 – clinician survey and co-design work; and stage 2 – randomised feasibility study with qualitative and economic components. Methods Stage 1 – survey of radiologists and urologists, and development of patient information materials. Stage 2 – patients identified across eight UK centres with small renal tumours (< 4 cm) were randomised (1 : 1 ratio) to ablation or active surveillance in an unblinded manner. Randomisation was carried out by a central computer system. The primary objective was to determine willingness to participate and to randomise a target of 60 patients. The qualitative and economic data were collected separately. Results The trial was conducted across eight centres, with a site-specific period of recruitment ranging from 3 to 11 months. Of the 154 patients screened, 36 were eligible and were provided with study details. Seven agreed to be randomised and one patient was found ineligible following biopsy results. Six patients (17% of those eligible) were randomised: three patients received ablation and no serious adverse events were recorded. The 3- and 6-month data were collected for four (67%) and three (50%) out of the six patients, respectively. The qualitative substudy identified factors directly impacting on the recruitment of this trial. These included patient and clinician preferences, organisational factors (variation in clinical pathway) and standard treatment not included. The health economic questionnaire was designed and piloted; however, the sample size of recruited patients was insufficient to draw a conclusion on the feasibility of the health economics. Conclusions The trial did not meet the criteria for progression and the recruitment rate was lower than hypothesised, demonstrating that a full trial is presently not possible. The qualitative study identified factors that led to variation in recruitment across the sites. Implementation of organisational and operational measures can increase recruitment in any future trial. There was insufficient information to conduct a full economic analysis. Trial registration Current Controlled Trials ISRCTN31161700. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 81. See the NIHR Journals Library website for further project information.


2021 ◽  
Vol 14 (4) ◽  
pp. e241091
Author(s):  
Ioannis Tsikopoulos ◽  
Dimitrios Ioannis Papadopoulos ◽  
Konstantinos Charitopoulos ◽  
Chrysovalantis Gkekas

We presented an extremely rare entity of ‘hybrid’ oncocytoma and collecting duct (Bellini) carcinoma. The intratumoural coexistence of benign and malignant cells may lead to false diagnosis and suboptimal treatment of an aggressive tumour. Diagnosis may be challenging if only based on imaging modalities. Even the established value of targeted renal biopsy may be questioned in such scarce cases. Consequently, active surveillance for small renal tumours shall not considered a widely safe management.


JAMA ◽  
2020 ◽  
Vol 324 (17) ◽  
pp. 1747
Author(s):  
Rishi Deka ◽  
P. Travis Courtney ◽  
J. Kellogg Parsons ◽  
Tyler J. Nelson ◽  
Vinit Nalawade ◽  
...  

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Andrew McIntosh ◽  
Pranav Parikh ◽  
Anthony Tokarski ◽  
Eric Ross ◽  
David Chen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document